ArticleHemaSphere2021

Pharmacological Inhibition of Insulin Growth Factor-1 Receptor (IGF-1R) Alone or in Combination With Ruxolitinib Shows Therapeutic Efficacy in Preclinical Myeloproliferative Neoplasm Models.

Titiksha Basu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.